CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,909 enrolled
Drug / intervention
bisoprolol/perindopril FDCdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03730116
NCT03730116N/ACompleted
CompareCT.gov

Multicenter Observational Open Program. Assessment of the Efficacy and Tolerability of the Fixed-dose Combination of Bisoprolol/Perindopril in Patients With Arterial Hypertension and Stable CAD in Daily Clinical Practice (STYLE)

Servier Russia·observational·Posted Nov 5, 2018·Updated Jan 13, 2021

In Brief

An observational study evaluating bisoprolol/perindopril FDC for Arterial Hypertension and CHD - Coronary Heart Disease. Completed, enrolled 1,909 participants across 1 site.

Detailed Summary

Study objective - to assess the efficacy, tolerability and adherence of bisoprolol/perindopril FDC in patients with HT and stable CAD in everyday practice. Type of the program: multicenter, observational, uncontrolled, open program. The program will involve 480 general practitioners (GPs) and cardiologists from the primary care facilities.Each doctor includes four patients. It is planned to include not less than 1920 patients in total.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Hypertension, CHD - Coronary Heart Disease
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedNov 5, 2018
Enrollment StartNov 14, 2018
Primary CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.7 years ago

Interventions

bisoprolol/perindopril FDCdrug

the first and only single-pill combination of beta-blocker and ACE inhibitor